FATE - Company ID 0001434316
FATE THERAPEUTICS INC trades as FATE. In its fiscal 2025 annual report the company posted revenue of $6.65M, down 51.2% from the prior year and net income of -$136.31M. This page tracks FATE THERAPEUTICS INC through 826 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years FATE THERAPEUTICS INC's revenue grew from $4.40M to $6.65M, a compound annual growth rate of 4.7%. Net profit margin compressed from -760.2% to -2051.1% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider sale notice | 144 | 2026-05-20 |
| Insider sale notice | 144 | 2026-05-20 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| Insider trade | 4 | 2026-05-07 |
| Insider trade | 4 | 2026-05-06 |
The largest companies sharing FATE THERAPEUTICS INC's SEC industry classification (biological products, (no diagnostic substances)).
FATE THERAPEUTICS INC reported revenue of $6.65M for fiscal year 2025, a decrease of 51.2% year over year.
In its latest fiscal year FATE THERAPEUTICS INC reported a net loss of $136.31M.